Cardiovascular & Hematological Agents in Medicinal Chemistry - Online First
Description text for Online First listing goes here...
-
-
Ceramides and Oxidized Lipids: Convergent Mediators of Cardiometabolic Pathogenesis
Available online: 10 November 2025More Less
-
-
-
Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy
Authors: Sunil Sahu, Pankaj Minj, Dhansay Dewangan, Swarnlata Saraf and Rakesh TirkeyAvailable online: 03 October 2025More LessHypertension, a prevalent cardiovascular condition, increases the risk of strokes and myocardial infarctions by inducing elevated blood pressure. Its prevalence has risen, particularly in low- and middle-income nations. The incidence of hypertension in adults is higher in low- and middle-income countries compared to high-income nations. One significant class of antihypertensive drugs is α1-adrenoceptor antagonists, which inhibit α1-adrenergic receptors and promote vasodilation. Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity.
-
-
-
The Antioxidant and Anti-lipidemic Potential of Angiotensin-converting Enzyme Inhibitor (Ramipril) in L-NAME Hypertensive Rats
Authors: Esther Oluwasola Aluko, Ezekiel Etim Ben and Grace Edet BasseyAvailable online: 21 August 2025More LessIntroductionHypertension is associated with oxidative disturbances and often coexists with metabolic disorders like hyperlipidemia. Some antihypertensive drugs, particularly angiotensin-converting enzyme (ACE) inhibitors, offer benefits beyond lowering blood pressure by addressing related conditions. This study aimed to investigate the effects of ACE inhibitors on oxidative stress and dyslipidemia induced by L-NAME hypertension in rats.
MethodsFifteen male Wistar rats (150–170 g) were divided into three groups. Group 1 received 10 mL/kg distilled water (control), while Groups 2 and 3 were orally administered 60 mg/kg of L-NAME (L-NAME60) for eight weeks to induce hypertension. After this period, Group 2 continued to receive L-NAME60 plus distilled water (HYP), and Group 3 received L-NAME60 plus ramipril (10 mg/kg) (RMHYP) for an additional five weeks. Blood pressure was measured using the tail-cuff method. Serum oxidative stress markers and lipid profiles were analyzed by spectrophotometry.
ResultsThe blood pressure significantly decreased in RMHYP compared to HYP. Malondialdehyde concentration significantly decreased, and antioxidant enzyme levels significantly increased in RMHYP compared to HYP. Serum lipid profiles showed a significant decrease in total cholesterol and triglycerides, as well as atherogenic indices, but a significant increase in high-density lipoprotein cholesterol levels in RMHYP compared to HYP.
DiscussionThis research shows that ramipril not only lowers blood pressure but also significantly reduces oxidative stress and dyslipidemia in L-NAME hypertensive rats, indicating its potential as an effective treatment for metabolic syndrome.
ConclusionThe findings of this study demonstrate that angiotensin-converting enzyme inhibitors (ramipril) have the ability to act as both an antioxidant and an anti-dyslipidemic agent in hypertensive conditions.
-